Previous cell subfractionation studies have indicated that bd-2 is an iuner mitochondrial membrane protein. We have sought to determine the ultrastructural localization of bd-2 protein in lymphoma and breast carcinoma cell lines and biopsy m a t e d known to overexpm bd-2 using immunoelectron miaoscopy. To avoid the possibility of processing artifaas, samples were prepared by three diff'erent methods: progressive lowering of temperature, ayosectioning, and freeze-substitution. In all instances the labeling of bd-2 protein was relatively weak but the distribution the same. In both lymphoma and breast carcinoma tissues, bd-2 protein was detected on the periphery of mitochondria: little label-* ing of either the mitochondrial matrix or cristae could be detected. Labeling was also detected on the perinuclear membrane and throughout the cytoplasm, as also indicated by confocal microscopy. These data therefore indicate that bd-2 protein can be detected at several intracellular sites and that at the likely functional destination, the mitochondria, there appears to be, contrary to expectations, a preferential association with the outer membrane. ( J Hisrochem Cytochem  40:1819-1825, 1992) 
Introduction
The bcl-2 gene was first described in follicular B-cell lymphomas with the t(1418) translocation (1) . This translocation brings the bcl-2 gene to the immunoglobulin heavy chain locus (1) (2) (3) . The resultant fusion gene is deregulated and leads to overexpression of the mRNA and protein (4,5).
The bcl-2 gene codes for a 25 KD protein which has been implicated in the control of cell death by apoptosis. In normal tissues, expression of bcl-2 is restricted to cells and tissues that are characterized by apoptotic cell tummr (6) . Therefore, immunocytochemical staining reveals bcl-2 expression in cells of lymphoid germinal centers, proliferative precursor cells in the bone marrow, glandular epithelium of the breast, thyroid, and prostate, and small crypt cells in the small and large intestine (6) . In both normal and neoplastic tissues and in experimental situations, expression or overexpression of the bcl-2 gene product appears to protect cells from death by preventing or delaying apoptosis. In experimental situations overexpression of bcl-2 in an IL3-dependent line deprived oflL3 has been demonstrated to block death by apoptosis (6) . Trans-genic mice transfected with the bcl-2 gene accumulate large numbers of small non-cycling B-cells (7) and later go on to develop tumors associated with myc rearrangements (8) . Similarly, transgenic mice containing both myc and bcl-2 transgenes show a marked hyperproliferation of pre-B-and B-cells, and develop tumors (9) . The precise functions of bcl-2 are not clear, and an important step in understanding the activity of this protein is to accurately define its cellular localization. Although bcl-2 has been reported as a cell membrane or a perinuclear endoplasmic reticulum component ( 5 ) , a mitochondrial location has been reported by several authors (10,ll). The latter authors determined by sucrose gradient fractionation and hypotonic lysis of extracts from the RG7 cell line that bcl-2 cosegregated with the enzyme succinate dehydrogenase and was therefore likely to be a component of the inner mitochondrial membrane. To further define the distribution of this protein, bcl-2 was localized at the ultrastructural level using a variety of preparative methods on several cell types.
Materials and Methods

Cell Lines ana' Solid Tifwes
Cell lines used in the study were the lymphoma-derived SU-Dm4 (12). K422 (13) . and K231, all ofwhich have a 14;18 translocation, and the breast tumor cell line MCF7 (14). which overexpresses bcl-2. Cells were maintained in RPMI medium with 10% fetal calf serum in 5% C02. Samples of human non-Hodgkin's lymphomas and breast tumors were obtained within 1 hr of resection and processed as described below.
AntibodieJ
Murine monoclonal antibodies (MAb) were raised against a synthetic peptide of bcl-2 corresponding to amino acids 41-54. Details of this procedure and evidence for specificity of the antibodies have been published (10,15). The studies reported here used antibody #IO0 (hybridoma supernatant). Similar results were obtained with antibodies WO and #124, and no improvements in staining intensity were observed by pooling all three antibodies.
Immunofluorescent Staining
Cultures of lymphoma cell lines K422 and S U -D m 4 were either prepared as cytospins or fixed and labeled in suspension. Cytospins were fixed in acetone and labeled with antibody #loo. followcd by sheep anti-mow-FITC conjugate (Amenham International; Little Chalfont. UK). For labeling in suspension, cells were centrifuged (500 x g) and re-suspended for 20 min in 4% paraformaldehyde in PBS. pH 7.4. After a PBS wash. the cells were permeabilized for 3 min in 0.2% Triton X-100 in PBS and given a further wash in PBS. The cells were labeled with mouse MAb #lo0 diluted 1:1 in PBS plus 0.5% bovine serum albumin (PBS-BSA) (Sigma; Poole, UK) for 60 min. After a PBS wash, the cells were incubated first in biotinylated sheep anti-mouse immunoglobulin (Amenham International) diluted 1:30 in PBS-BSA, washed in PBS. and finally incubated in streptavidin-FITC (Amenham International) diluted 1:30 in PBS-BSA. Labeled cells were mounted in Citifluor (Citifluor; London. UK). Control preparations were incubated in the absence of primary antibody or with MAb #lo0 absorbed with synthetic peptide (AA 41-54) at a molar ratio of peptide:antibody of 1:l or >1:1 before staining. Immunostaining was evaluated by both conventional and confocal microscopy.
El'ectron Microscopy
Cell lines were prepared for electron microscopy by centrifugation (100 x g for 5 min). re-suspension in 2% gelatin in PBS. and repeat centrifugation (100 x g for 5 min). followed by cooling to 4°C to form a pellet held in a gelatin matrix. Tumor biopsy specimens were collected within 1 hr and cut in 1-mm cubes. Cells plus gelatin or tumor biopsies were then treated identically and prepared by three separate methods to remove the possibility that processing for ultrastructural immunocytochemistry might result in redistribution of the bcl-2 protein.
Progressive Lowering of Temperature (PLT). Samples for embedding by the PLT method (SU-DHL4. K422. K231. human lymphoma biopsy, human breast tumor biopsy) were fixed for 1 hr in 2% paraformaldehyde plus 0.05I glutaraldehyde in PBS and stored for up to 24 hr in PBS. They were dehydrated in ethanol and embedded in Lowicryl HM2O at -5O' C by the PLT method as previously described (16).
Thawed Cryoxctions. The method was essentially as defined by Tokuyasu (17) as previously described (18). Samples (SU-DHL4) fixed as for PLT above were cryoprotected in 2.3 M sucrose in PBS and frozen in liquid nitrogen (LNz). Samples were sectioned at -1Oo'C with a diamond knife and an anti-static device (Diatome: Leica, Milton Keynes, UK) in a Reichert FC4IUltracut E (Leica). Sections were collected on droplets of 2.3 M sucrose on carbon-coated, formvar-gold.grids. thawed, and stored on 2% gelatin in PBS at 4'C for up to 48 hr.
Freeze-subsrimtion. Samples (MCF7, SU-DHL-4) were procesxd as described previously (19) . Briefly, after rapid freezing on an LNz-cooled copper blodc (Reichcrt KF80; Leica), the frozen cells were transferred to a Reichert CS Auto (Leica) and substituted at -8O'C either in methanol for 30 hr or in acetone for 5 days. Substituted samples were warmed to -5O'C and embedded in Lowicryl HM20. which was polymerized at -50°C by W light.
Immunocytochemistry
Sections were floated on (cryosections) or immersed in (resin sections) 20 pl of blocking buffer [PBS plus 0.8Oh bovine serum albumin, 5 % fetal calf serum (FCS). 0.1% fish gelatin] for 30 min. They were transferred to droplets of MAb #IO0 used diluted 1:1 in blocking buffer and incubated overnight at room temperature in a moist chamber. After three 5-min washes in washing buffer (blocking buffer minus FCS), the bound antibody was detected by incubation for 90 min with goat anti-mouse IgGs conjugated to 5-nm colloidal gold (Amersham). A further three 5-min washes in washing buffer were followed by three 2-min washes in ultrapure (18 MQ) water and the 5-nm gold was silver-enhanced (IntenSE; Amcrsham) for 6 min. Grids were washed in ultrapure water (three times for 2 min). dried, and contrasted with uranyl acetate and lead citrate (LKB Ultrostainer; Leica). Control sections were incubated in the absence of the primary antibody and also with the primary antibody replaced by an alrernative MAb (used at a similar dilution) recognizing a protein not expressed in the cells tested.
Immunolabeling of cryosections was as for resin sections, except that the 5-nm gold conjugate was not silver-enhanced. After immunolabeling the grids were washed in ultrapure water (three times for S min), floated on droplets of 3% (wlv) uranyl acetate in methyl cellulose (25 cp; Aldrich Chemical, Gillingham, UK) for 15 min. collected in copper loops, and allowed to air-dry Scctions were m i n e d in a Philips CMtO electron microscope at an accelerating voltage of 80 kV.
To determine the proportions of colloidal gold label bound to the cell compartments described. counts were made of the location of gold partic l a on images of SU-DHL4 prepared by PLT and freeze-substitution. Electron micrognphswere illuminated on a light box and werlaid with an acetate sheet. Every gold particle was counted. marked. and assigned to a cell compartment. For a particle to be scored as associated with the mitochondrial periphery, it had to be within one gold particle diameter of the mitochondrial periphery.
Levels of nonspecific labeling were determined from electron micrograph negatives of control sections of PLT-embedded K231 cells taken at a magnification of 5.2 k and projected x 6 onto a 100-point grid. The relative areas of cells and blank resin were measured for each negative, and the silver-enhanced gold parricla in each area were counted. The number of gold parricla per square pm was calculated. The total a m analyzed per control was 1170 square pm. T h e control results were compared with KCtions labeled with MAb #loo.
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Results
Immunofluorescence
Labeled preparations of lymphoma cell lines K422 and SU-DHG4 gave similar staining pattems with bcl-2 MAb #100. bcl-2 antigen was present in the perinuclear envelope as wcll as in regions of the cytoplasm (Figure 1) . All staining could be blocked by adding to antibody synthetic bcl-2 peptide (AA 41-54) as competitor before staining at a molar ratio of peptide to antibody of 1:1 or >k1.
Elecmn Microscopy
Initial immunolocalization experiments on PIT-prepared samples of the cell lines SU-DHL4. K231. and K422 gave lower labeling intensity than predicted from staining of the same cells in cytospin . . l n l l l s n "---. preparations (Figure I) , with the amount of label varying from cell to cell, although background labeling of nuclei and blank resin with MAb #lo0 was extremely low. Analysis of a large number of cells indicated that the bcl-2 was localized in three cell compartments: the perinuclear membrane, the peripheral region of mitochondria and, to a lesser extent, throughout the cytoplasm, often associated with membrane structures (Figure 2 ). All three cell lines showed a similar distribution of label. Further confirmation of the localization of bcl-2 was obtained by immunolabeling a fresh lymphoma biopsy specimen (Figure 3 ) embedded by PLT.
To ensure that the localization of bcl-2 seen on the PLTembedded samples was not a processing artifact, the same cell line was prepared by two further methods. The results of immunolabeling sections of SU-DHG4 prepared by cryosectioning (aldehyde fixation but no resin embedding) ( Figure 4 ) and freeze-substitution (no aldehyde fixation, but resin embedding) was not detectably different from the results seen with the PLT-embedded resin sections. No increase in immunolabeling sensitivity was detected by either method.
A proportion of human breast tumors appear to express bcl-2 (BA Gusterson, personal communication). The human breast tumor cell line MCF-7 was prepared for immunocytochemistry by rapid freezing followed by freeze-substitution in both methanol and acetone to allow for possible modulation of the antigen by different substitution agents. A similar localization pattern was obtained as seen with SU-DHL4 in samples substituted in either substitution medium and with the fresh breast tumor biopsy specimen (Figure 5) . The results of an analysis of the localization of silver-enhanced gold particles on sections of SU-DHL-4 prepared by both PLT and freeze substitution are given in Table 1 .
Between 48 and 54% (depending on the processing method) of the total label was present on the peripheral region of mitochondria, with only 5 4 % of the label localized to the mitochondrial matrix. Between 9 and 11% of the label was localized to the nuclear membrane, with the remaining 2 6 4 6 % of the label associated with the remainder of the cytoplasm. In many cases the cytoplasmic labeling appeared associated with membrane structures. Nuclear labeling was extremely low, indicating low levels of nonspecific binding.
Therefore, independent of cell line, tissue or preparation method, the distribution of colloidal gold particles appeared to be similar. Where the same cell line was processed by different methods, the intensity of immunolabeling was similar. The analysis of control sections of PLT-embedded K231 cells gave the number of particles per pmZ on the immunolabeled sections as 0.003 (cells) and 0 (resin) for the sections incubated without primary antibody, 0.02 (cells) and 0.02 (resin) for the inappropriate primary antibody. In contrast, the figures were 0.42 for cells and 0.01 for resin using MAb #loo.
Discussion
Initial results obtained by electron microscopy gave reproducible results, but relatively low levels of labeling were observed compared with that seen in the same cells stained by immunocytochemistry for light microscopy. The most likely explanation for the discrepancy is lability of the bcl-2 epitopes detected by monoclonal antibodies. Similar results have been obtained with another MAb, 6C8 (S. Korsmeyer. personal communication to MFG, November 1991) . Samples of SU-DHL-4 cells were initially prepared by the PLT method, which involves a brief aldehyde fixation, followed by low-temperature embedding and polymerization at -50°C.
The fixation, solvent dehydration, and resin embedding all have the potential to reduce antigenicity, and the same cell line was there-fore prepared by alternative methods. Cryosections were prepared after aldehyde fixation, but avoiding dehydration and resin embedding, and freeze-substitution replaced aldehyde fixation with rapid freezing followed by low-temperature resin embedding. Immunolabeling of SU-DHL-4 prepared by the three methods gave similar antigen localization and levels of labeling. Further immunolocalization of bcl-2 on two additional lymphoma cell lines, a lymphoma biopsy, a breast tumor cell line, and a breast tumor biopsy specimen all revealed similar antigen localization.
The results described are in agreement with a previous description of a peri-nuclear distribution for bcl-2 ( 5 ) . The association of label with mitochondria in all cell types studied also supports previous studies (10). However, the high proportion of the total gold label (approximately 50%) on the peripheral region of mitrochondria is at odds with the description of bcl-2 as being predominantly associated with the inner mitochondrial membrane. The reason for the discrepancy in the location of bcl-2 is not clear, but it was in order to remove the possibility that the outer mitochondrial membrane localization was an artifact of one cell line or processing method that the range of samples and methods reported here was necessary.
Although a small number of gold particles were localized to the mitochondrial matrix (approximately 10%). the consistency of the peripheral location of the majority of the gold label, regard- less of cell type and processing method, indicates that bcl-2 is associated with the outer region of the mitochondria. Indeed, it is possible that much of the labeling of the mitochondrial matrix is artifactual. resulting from grazing sections of mitochondria giving poor membrane detail, but bcl-2 localization apparently within the matrix.
Whether bcl-2 is present on the inner or outer face of the outer mitochondrial membrane, or perhaps is associated with the specialized contact region between inner and outer mitochondrial membranes, cannot readily be resolved from these data. From images of routinely prepared SU-DHL-4, the average distance between the inner and outer membranes is 15 nm. The 5-nm colloidal gold probes used in this study have a potential worst-case resolution of 20-28 nm (20) resulting from the presence of two immunoglobulin molecules between the antigenic site and the gold particle.
The precise localization of bcl-2 protein in mitochondria obviously has important implications for its function. At present we are unable to resolve the discrepancy between our data and those of Hockenbery et al. (6) , particularly in view of the very different techniques used. One possibility is that bcl-2 has a variable accessibility of epitopes dependent on associations with other proteins (21) and that this critically influences whether and where in a cell bcl-2. as an antigen, is detectable in processed sections and in detergent extracts. A further alternative is that bcl-2 is localized in Analysis of the localization of bcl-2 on PLT-embedded and fieeze-substituted SU-DHL-4 specialized regions of the inner mitochondrial membrane that are in close apposition to the outer mitochondrial membrane, but not present on the mitochondrial christae. In a wider context, tumor cells overexpressing bcl-2 are a potential target for clinical therapy (22), but a clear understanding of the subcellular distribution and mode of action of bcl-2 are vital in devising novel therapeutic strategies.
